Quantcast

The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources


Shutterstock photo

For Immediate Release

Chicago, IL - November 21, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Sanofi SNY , Novo Nordisk NVO , NVIDIA NVDA , Fifth Third Bancorp FITB and Continental Resources CLR .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Tuesday's Analyst Blog:

Top Stock Reports for Sanofi, Novo Nordisk & NVIDIA

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Sanofi, Novo Nordisk and NVIDIA. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see  all of today's research reports here >>>

Sanofi 's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past three months, gaining +4.8% vs. +3.4%. Sanofi's earnings and sales beat estimates in the third quarter. As anticipated, Sanofi returned to sales growth in the quarter.

The Zacks analyst thinks its focus on streamlining operations and pursuing business development deals is encouraging. The company has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. Particularly, sales prospects of Dupixent provide reason for optimism, since it could prove to be an important growth driver.

Meanwhile, the acquisitions of Ablynx and Bioverativ have strengthened Sanofi's position in the rare blood disorders market. The performance of the Vaccines and Consumer Healthcare franchises has also improved of late. However, headwinds include a bleak outlook for the Diabetes franchise, generic competition for many drugs and slower-than-expected uptake of new products like Praluent.

Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry year to date (down -15.3% vs. +9%). Novo Nordisk reported in line earnings but beat sales estimates in third-quarter 2018. However, the Zacks analyst remains optimistic about Ozempic and results for oral semaglutide. It is looking forward to make the first oral GLP-1 treatment available for people with type II diabetes.

The company also made some organizational changes aimed at boosting innovation in its R&D organization and redirecting resources in other parts of the organization to drive growth further. The company's acquisition of Ziylo will provide it with the latter's synthetic glucose binding molecules that will enable it to develop glucose responsive insulins. The company's expansion of its biopharm business also bodes well.

NVIDIA 's shares have underperformed the Zacks General Semiconductor industry year to date (down -25.2% vs. -8.3%). NVIDIA recently reported dismal third-quarter fiscal 2019 results with both top and the bottom-line results falling short of expectations.

Weakness in the Gaming segment, affected by an excess inventory of midrange Pascal products, impacted the company's results. Inventory level of midrange Pascal gaming cards remained higher-than-expected as demand from gamers failed to grow rapidly to offset the soft crypto currency-related requirement. Consequently, shipments were badly hurt as the price of graphic cards remained elevated.

However, the Zacks analyst thinks NVIDIA's sustained efforts toward attaining a robust position in several emerging industries remain encouraging. Growth opportunities in ray-traced gaming, rendering, high-performance computing, AI and self-driving cars are expected to be the company's consistent tailwinds.

Other noteworthy reports we are featuring today include Fifth Third Bancorp and Continental Resources.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.  See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Fifth Third Bancorp (FITB): Free Stock Analysis Report

Sanofi (SNY): Free Stock Analysis Report

Novo Nordisk A/S (NVO): Free Stock Analysis Report

Continental Resources, Inc. (CLR): Free Stock Analysis Report

NVIDIA Corporation (NVDA): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: FITB , SNY , NVO , CLR , NVDA



More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research










Research Brokers before you trade

Want to trade FX?